Refine
Has Fulltext
- yes (70)
Is part of the Bibliography
- yes (70)
Year of publication
Document Type
- Journal article (70)
Language
- English (70)
Keywords
- multiple myeloma (5)
- apoptosis (4)
- gene expression (4)
- Hodgkin lymphoma (3)
- Medizin (3)
- Activation (2)
- CD30 (2)
- CXCR4 (2)
- NFATc1 (2)
- T cells (2)
- T-cell lymphoma (2)
- amplicon sequencing (2)
- anaplastic large cell lymphoma (2)
- cancer (2)
- cell staining (2)
- cell-cycle arrest (2)
- flow cytometry (2)
- gene regulation (2)
- lymphoma (2)
- machine learning (2)
- metastasis (2)
- survival (2)
- thymus (2)
- 3D lung tumor tissue models (1)
- AKT-signaling (1)
- ALCL (1)
- ALK-1 (1)
- AOM/DSS (1)
- ATG7 (1)
- Antibodies (1)
- B cell malignancies (1)
- B cell receptor (BCR) (1)
- B cells (1)
- B-MYB (1)
- B-cell lymphoma (1)
- BIRC7 (1)
- Bioluminescence imaging (1)
- Biomarker (1)
- Bone marrow cells (1)
- Bone marrow transplantation (1)
- Breast-cancer (1)
- Bruton Tyrosine Kinase (1)
- Burkitt lymphoma (1)
- Burkitt lymphoma (BL) (1)
- B‐cell lymphoma (1)
- CD/metabolism (1)
- CD274 (1)
- CD319 (1)
- CD40 ligand (1)
- CRC (1)
- CRISPR/Cas9 (1)
- CS1 (1)
- CX5461 (1)
- CXCR4/SDF-1 (1)
- Cancer (1)
- Cancer genetics (1)
- Cancer treatment (1)
- Chains (1)
- Clonality (1)
- Cushings syndrome (1)
- DHAP (1)
- DNA hypermethylation (1)
- DNA methylation (1)
- Defined burkitts lymphoma (1)
- Delta Repertoire (1)
- Design (1)
- EBER in situ hybridization (1)
- EBV (1)
- EMT (1)
- EZH1 (1)
- EZH2 (1)
- Epitope (1)
- Epstein-Barr virus (1)
- Expression (1)
- FDG PET/CT (1)
- FFPE (1)
- Fak regulation (1)
- Frequency (1)
- GIST (1)
- Gene-expression (1)
- Genome wide analysis (1)
- GvHD (1)
- H3K27me3 (1)
- HD (1)
- Hans algorithm (1)
- High-resolution (1)
- Histone deacetylase inhibition (1)
- IL-17 (1)
- IRF4 (1)
- Ibrutinib (1)
- Induced apoptosis (1)
- Intestinal Intraepithelial Lymphocy (1)
- JAK inhibitor (1)
- KIT (1)
- KRAS (1)
- KRAS biomarker signatures (1)
- Kidney cancer (1)
- LESA (1)
- Ligand (1)
- Lipom (1)
- Lung-cancer (1)
- LyP (1)
- Lymph2Cx assay (1)
- Lymphoma (1)
- Lymphomas (1)
- MEK/ERK-signaling (1)
- MIZ1 (1)
- MTB (1)
- MTCH2 (1)
- MTX (1)
- MYC (1)
- Malignancies (1)
- Mantle cell lymphoma (1)
- Mechanisms (1)
- Medical research (1)
- Microarray (1)
- Migration (1)
- Molecular pathogenesis (1)
- Multiple (1)
- Myb-MuvB (1)
- Myeloma cells (1)
- Myelomas (1)
- NF-Kappa-B (1)
- NFAT (1)
- NGS (1)
- NLPHL (1)
- Nuclear expression (1)
- Organoids (1)
- PCI-32765 (1)
- PET (1)
- PLAG1 rearrangement (1)
- PTCL (1)
- Pathogenesis (1)
- Pathway (1)
- Phase- (1)
- Positron emission tomography (1)
- Profiling (1)
- Prognosis (1)
- Proliferation (1)
- Promoter (1)
- R-CHOP (1)
- RCC (1)
- RNA probe (1)
- RNAPOL1 (1)
- Renal cell carcinoma (1)
- Rituximab plus (1)
- Riutximab (1)
- SGN-35 (1)
- Sox9 (1)
- Spleen (1)
- Sprue (1)
- Stromal cells (1)
- Survival (1)
- T cell receptors (1)
- T(H)17 cells (1)
- T-cell non-Hodgkin's lymphomas (1)
- T-cell transfer (1)
- T-follicular regulatory cell (1)
- TCR (1)
- TCR signaling cascade (1)
- Targeted Therapies (1)
- Targets (1)
- Th17 (1)
- Transcription-factor (1)
- Translational research (1)
- Tregs (1)
- Tumor Microenvironment (1)
- Tumour markers (1)
- USP9X (1)
- Usage (1)
- XIAP (1)
- YAP (1)
- [\(^{68}\)Ga] pentixafor (1)
- abnormalities (1)
- actin (1)
- activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL) (1)
- acute graft-versus host disease (1)
- acute myeloid leukaemia (1)
- adenomas (1)
- adrenal tumor (1)
- adrenocortical cancer (1)
- alloreactive T cells (1)
- alternative splicing (1)
- aluminum granuloma (1)
- amplifications (1)
- anaplastic large cell lymphoma (ALCL) (1)
- anaplastic medulloblastoma (1)
- animal model (1)
- anti-CD30 drug conjugate (1)
- anti-inflammatory cytokines (1)
- antigen loss (1)
- antigens (1)
- antioxidant function (1)
- aortic adventitia (1)
- autoimmune disease (1)
- autologous transplantation (1)
- autophagy (1)
- biosynthesis (1)
- bone disease (1)
- bone marrow cells (1)
- boolean in silico models (1)
- brain tumor (1)
- breast cancer (1)
- c-myc (1)
- cancer care (1)
- cancer detection (1)
- cancer diagnosis (1)
- cancer metabolism (1)
- cancer stem cells (1)
- cancers and neoplasms (1)
- carcinogenesis (1)
- carcinoma (1)
- carcinomas (1)
- case report (1)
- caspase-3 (1)
- catenin (1)
- cell binding (1)
- cell cycle and cell division (1)
- cell death (1)
- cell of origin (1)
- cells (1)
- chemokine receptor (1)
- children (1)
- chromosomes (1)
- chronic IBD model (1)
- classical Hodgkin lymphoma (1)
- classification (1)
- combined therapy (1)
- comparative genomic hybridization (1)
- complement system (1)
- consensus DNA (1)
- cutaneous T-cell-lymphoma (1)
- cyclophsophamide (1)
- cyclosporin A (1)
- cytotoxicity (1)
- damage (1)
- damage responses (1)
- deletions (1)
- diagnostics (1)
- diffuse large B-cell lymphoma (1)
- disease (1)
- distinct (1)
- drug resistance (1)
- ectopic lymphoid follicle (1)
- effector Treg (eTreg) (1)
- enhancer (1)
- enzyme-linked immunoassays (1)
- ephitelial cells (1)
- epigenetics (1)
- epithelium (1)
- expression (1)
- extramedullary disease (1)
- features (1)
- fluorescence in situ hybridisation (1)
- follicular lymphoma (1)
- forecasting (1)
- gRNA-only (1)
- gastrointestinal infections (1)
- gene (1)
- genetic loci (1)
- genomic aberrations (1)
- germline mutation (1)
- glioblastoma (1)
- grade 3B (1)
- group 3 (1)
- growth patterns (1)
- helper T cells (1)
- hemophagocytosis (1)
- high numbers (1)
- high-dose chemotherapy (1)
- high-resolution analysis (1)
- human genome (1)
- imaging (1)
- immune checkpoint blockade (1)
- immunohistochemistry (1)
- immunohistochemistry techniques (1)
- immunotherapeutics (1)
- in vivo imaging (1)
- in-vitro (1)
- in-vivo (1)
- independent predictor (1)
- inflammation-induced tissue demage (1)
- invasion (1)
- involvement (1)
- kidney cancer (1)
- kidneys (1)
- kinase (1)
- large cell transformation (1)
- latency type (1)
- lesions (1)
- lineage (1)
- lipoblastoma (1)
- livin (1)
- lymph node stromal cells (1)
- lymph node transplantation (1)
- lymphohistiocytosis (1)
- lymphoid aggregate (1)
- lymphoid hyperplasia (1)
- lymphomatoid papulosis (1)
- mTOR (1)
- major histocompatibility complex (1)
- malignancies (1)
- malignant tumors (1)
- mantel cell lymphoma (1)
- mantle cell lymphoma (1)
- marcophages (1)
- marrow transplantation (1)
- mast cells (1)
- mastocytosis (1)
- measles virus (1)
- meningeal inflammation (1)
- mesenteric lymph node (1)
- mesentery (1)
- metabolism (1)
- methylation (1)
- miR-126 (1)
- miR-21 (1)
- miRNA (1)
- mice (1)
- microenvironment (1)
- mitochondrial DNA (1)
- mitosis (1)
- mitotic genes (1)
- molecular subtypes (1)
- monoclonal antibody (1)
- mouse models (1)
- mtDNA (1)
- mutant p53 (1)
- mutation (1)
- myasthenia (1)
- myasthenia gravis (1)
- mycosis fungoides (1)
- naive T-cell gene editing (1)
- network (1)
- neutral loss (1)
- next generation sequencing (1)
- nodular lymphcyte (1)
- notch signaling (1)
- nuclear localization (1)
- obinutuzumab (1)
- organoids (1)
- orthotopic xenograft (1)
- outcomes research (1)
- outreach (1)
- p53 (1)
- p53-dependent apoptosis (1)
- p53-inducible regulator (1)
- pan-RCC (1)
- pancreatic cancer (1)
- panel sequencing (1)
- panel-sequencing (1)
- panniculitis (1)
- pathology (1)
- pathway (1)
- patient access (1)
- pediatric (1)
- pediatric lymphoma (1)
- peripheral T-cell (1)
- plasma cells (1)
- pleural mesothelioma (1)
- poor prognosis (1)
- positron emission tomography (1)
- precision oncology (1)
- primary cutaneous follicular B-cell lymphoma (1)
- pro-inflammatory cytokines (1)
- prognostic factor (1)
- progressive multiple sclerosis (1)
- pseudolymphoma (1)
- psoas muscle (1)
- rare SNP (1)
- real world data (1)
- receptor tyrosine kinases (1)
- refractory/relapsed lymphoma (1)
- regression analysis (1)
- regulatory T-cells (1)
- relapse (1)
- renal cancer (1)
- renal cell carcinoma (1)
- restoration (1)
- retroperitoneal tumor (1)
- reverse transcriptase-polymerase chain reaction (1)
- ribosome (1)
- seminoma (1)
- senescence (1)
- serum (1)
- slice culture (1)
- stemness (1)
- suppression (1)
- surgery (1)
- surgical and invasive medical procedures (1)
- surgical oncology (1)
- systemic and cutaneous CD30+ lymphoproliferations (1)
- systemic sclerosis (1)
- target validation (1)
- targeted (1)
- targeted combination therapy (1)
- targeted sequencing (1)
- targeted therapies (1)
- theranostics (1)
- thymic carcinoma (1)
- thymic epithelial tumor (1)
- thymitis (1)
- thymoma (1)
- tofacitinib (1)
- transcription (1)
- transcriptional repression (1)
- transformation (1)
- translocation (1)
- treatment regimens (1)
- tumor heterogeneity (1)
- tumor microenvironment (1)
- tumor spheroids (1)
- tumor-vessel wall-interface model (1)
- tumorigenesis (1)
- tumormicroenvironment (1)
- tumors (1)
- ubiquitin (1)
- up regulation (1)
- vascular wall stem and progenitor cells (1)
- vascularization model (1)
- vasculogenesis (1)
- venetoclax (1)
Institute
- Pathologisches Institut (67)
- Medizinische Klinik und Poliklinik II (20)
- Comprehensive Cancer Center Mainfranken (10)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (7)
- Theodor-Boveri-Institut für Biowissenschaften (7)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (6)
- Urologische Klinik und Poliklinik (5)
- Medizinische Klinik und Poliklinik I (4)
- Kinderklinik und Poliklinik (3)
- Klinik und Poliklinik für Nuklearmedizin (3)
Sonstige beteiligte Institutionen
Delayed and limited administration of the JAKinib tofacitinib mitigates chronic DSS-induced colitis
(2023)
In inflammatory bowel disease, dysregulated T cells express pro-inflammatory cytokines. Using a chronic azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis model resembling ulcerative colitis, we evaluated whether and when treatment with the Janus kinase (JAK) inhibitor tofacitinib could be curative. Comparing the treatment with two and three cycles of tofacitinib medication in drinking water – intermittently with DSS induction – revealed that two cycles were not only sufficient but also superior over the 3-x regimen. The two cycles of the 2-x protocol paralleled the second and third cycles of the longer protocol. T cells were less able to express interferon gamma (IFN-γ) and the serum levels of IFN-γ, interleukin (IL)-2, IL-6, IL-17, and tumor necrosis factor (TNF) were significantly reduced in sera, while those of IL-10 and IL-22 increased under the 2-x protocol. Likewise, the frequency and effector phenotype of regulatory T cells (Tregs) increased. This was accompanied by normal weight gain, controlled clinical scores, and restored stool consistency. The general and histologic appearance of the colons revealed healing and tissue intactness. Importantly, two phases of tofacitinib medication completely prevented AOM-incited pseudopolyps and the hyper-proliferation of epithelia, which was in contrast to the 3-x regimen. This implies that the initial IBD-induced cytokine expression is not necessarily harmful as long as inflammatory signaling can later be suppressed and that time-restricted treatment allows for anti-inflammatory and tissue-healing cytokine activities.